A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG

Summary

This is a Phase Ib/II, open-label, head-to-head, age de-escalation dose-escalation, partially randomized trial to study the safety and immunogenicity of the candidate rabies vaccine ChAdOx2 RabG in healthy adults (age 18-45 years) and young children (age 2-6 years). ChAdOx2 RabG will be administered intramuscularly and licensed rabies vaccine will be given by intradermal injection.

Timeline

Start

2022-02-17

Primary completion

2028-09

Completion

2028-09

Publications

• Ritchie AJ, Hassan O, Urasa N, Apanga PA, Kimathi R, Kalinga WF, Mtaka IM, Lyimo RG, Shabani MM, Orliacq F, Berg A, Xiang Z, Ahmed S, Athuman T, Ertl HCJ, Olotu A, Douglas AD; RAB002 study team. Safety and immunogenicity of a single-dose adenovirus-vectored rabies vaccine over 1 year in adults and children in Tanzania: interim data from an ongoing, partly randomised, controlled, phase 1b/2 trial. Lancet Infect Dis. 2026 Apr 28:S1473-3099(26)00071-X. doi: 10.1016/S1473-3099(26)00071-X. Online ahead of print.

Drugs

Indications